$QCLS Cashflow Statement | Understand Stock

$QCLS

$0.46 -$0.01 (2.33%) Close

$QCLS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued interest/dividends
Accretion of debt discount
(Gain)/loss on sale of marketable securities
Gain on forgiveness of debt
Gain (loss) on sale of marketable securities
Gain on sale of marketable securities
Change in fair value of marketable securities
Change in fair value of derivatives
Change in fair value of warrants
Change in fair value of contingent consideration
Impairment of intangible assets
Loss on issuance of Series F-1 Convertible Preferred Stock
Loss on issuance of Series G Convertible Preferred Stock
Stock based compensation:
Option modification expense
Options/RSUs issued to directors
Options/RSUs issued to key employees
Options/RSUs issued to non-employees
Shares issued for services
Restricted stock units to non-employees

Change in assets and liabilities
Accounts receivables
Prepaid expenses
Trade and other payables
License fees payable
Operating leases
Deferred compensation payable

Net cash used in operating activities
Purchase of technology license
Purchases of marketable securities
Proceeds from sale of marketable securities
Net cash received in business combination
Net cash (used in investing activities
Cash flows from financing activities
Repayment of the line of credit – related party
Net proceeds from borrowings
Net proceeds from note payable
Redemption of Series F Convertible Preferred Stock
Dividends on Series F Convertible Preferred Stock
Premium on Series F Convertible Preferred Stock
Net proceeds from the issuance of Series F Convertible Preferred Stock
Net proceeds from the issuance of Series F-1 Convertible Preferred Stock
Net proceeds from issuance of common stock
Net proceeds from the issuance of Series G Convertible Preferred Stock
Net proceeds from the issuance of Series H Convertible Preferred Stock
Net proceeds from the exercise of warrants for common stock
Redemption of Convertible Preferred Stock
Premium on Convertible Preferred Stock
Dividend on Convertible Preferred Stock
Net cash provided by financing activities
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental cash flow information
Interest
Supplemental Schedule of Non-Cash Financing and Investing Activities
Operating lease right-of-use asset obtained in exchange for lease obligation
Investment in Oravax Medical, Inc.
Initial fair value of warrant liabilities pursuant to the issuance of Series F Convertible Preferred Stock and Warrants
Initial fair value of derivative liabilities pursuant to the issuance of Series F Convertible Preferred Stock and Warrants
Fair value of Series G Convertible Preferred Stock issued in-lieu of dividends
Initial fair value of derivative liabilities pursuant to the issuance of Series H Convertible Preferred Stock and Warrants
Contingent Consideration Payable for the issuance of Series I Convertible Preferred Stock
Initial fair value of the LightSolver technology license
Initial fair value of warrant liabilities pursuant to the issuance of Series F-1 Convertible Preferred Stock and Warrants
Initial fair value of derivative liabilities pursuant to the issuance of Series F-1 Convertible Preferred Stock and Warrants
Initial fair value of warrant liabilities pursuant to the issuance of Series G Convertible Preferred Stock and Warrants
Reclass of warrant liability to equity upon warrant modification for the Series F Warrants
Reclass of warrant liability to equity upon warrant modification for the Series F-1 Warrants
Reclass of warrant liability to equity upon warrant modification for the Series G Warrants
Modification of Series F Convertible Preferred Stock

Comments